Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
URGN
#1990
UroGen Pharma Ltd. - Ordinary Shares
38.2
6
USD
0.00%
Market Price
Sector:
Healthcare
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
-0.05%
Monthly Change
-11.54%
6 month change
+83.37%
Year Change
+101.37%
Previous Close
38.2
8
Open
37.8
2
Low
37.3
0
High
38.8
3
Markets
US Stock Market
Healthcare
Biotechnology
URGN
1D
1W
1M
3M
6M
YTD
1Y
5Y
Open full chart
Financials
Overview
Statement
Statistics
Documents
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
Current
Key stats
Total common shares outstanding
22.27 M
22.67 M
23.44 M
34.12 M
46.09 M
48.68 M
48.88 M
Valuation ratios
Enterprise value
348.49 M
171.21 M
244.66 M
522.55 M
441.4 M
1.15 B
1.84 B
Price to earnings ratio
—
—
1.79
4.29
3.6
-7.34
-17.76
Price to sales ratio
—
—
3.52
6.45
5.86
11.93
10.18
Price to cash flow ratio
—
—
2.25
5.74
4.72
-6.94
-10.96
Price to book ratio
—
—
2.21
6.73
51.87
-10.68
-3.66
Enterprise value to EBITDA ratio
-2.75
-1.87
-2.83
-6.58
-4.05
-8.15
-21.89
Profitability ratios
Return on assets %
-1.05
-0.93
-0.81
-0.57
-0.44
-0.77
-0.06
Return on equity %
-1.33
-13.17
1.23
1.57
14.41
1.46
0.11
Return on invested capital %
-1 235.54
-2 006.82
-1 488.99
-1 145.41
-1 526.09
-956.59
0.8
Gross margin %
91.45
89.27
101.4
107.87
104.67
103.07
97.51
Operating margin %
-1 074.15
-192.11
-141.35
-96.38
-124.28
-132.21
0.16
EBITDA margin %
-1 074.29
-190.38
-154.79
-116.84
-139.98
-149.57
-7.57
Net margin %
-1 088.94
-230.67
-196.33
-150.36
-162.92
-162.53
-21.24
Liquidity ratios
Quick ratio
5.3
4.9
5.21
5.24
5.81
3.65
3.41
Current ratio
5.39
5.11
5.39
5.42
6.01
4.01
3.8
Inventory turnover
—
—
0.19
0
—
—
—
Asset turnover
0.07
0.4
0.44
0.43
0.34
0.47
0.27
Solvency ratios
Debt to assets ratio
—
—
0.72
0.55
0.43
0.61
0.75
Debt to equity ratio
—
—
-1.09
-1.51
-13.83
-1.16
-1.44
Long term debt to total assets ratio
—
—
—
—
—
0.62
0.79
Long term debt to total equity ratio
—
—
—
—
—
-1.19
-1.51
Per share metrics
Operating cash flow per share
—
—
-3.84
-2.65
-2.26
-3.38
-3.23
EBIT per share
—
—
-3.84
-2.78
-2.55
-2.94
-1.73
EBITDA per share
—
—
-3.8
-2.76
-2.54
-2.94
-1.73
Total debt per share
—
—
4.28
3.42
2.86
2.54
3.77
Cash per share
—
—
4.38
4.91
5.64
2.5
2.14
Net current asset value per share
—
—
5.65
5.87
6.44
3.87
4.67
Tangible book value per share
—
—
-3.92
-2.26
-0.21
-2.19
-2.63
Working capital per share
—
—
4.6
4.79
5.37
2.9
3.44
Book value per share
—
—
-3.92
-2.26
-0.21
-2.19
-2.63
News
UroGen Pharma Stock: An Emerging GARP Stock (NASDAQ:URGN)
Here's Why You Should Add URGN Stock to Your Portfolio Now
Mining Stocks Like AngloGold Ashanti And Iamgold Invade IBD Watchlists
Harmony Gold Mining Joins IBD Sector Leaders; 18 Other Stocks Graduate To IBD Watchlists
Microsoft Rises, Defying Weak Market; Leads 17 To Top Growth Stock Lists
Making Drugs With AI: Biopharma Giants Gear Up For New Arena
Wall Street Analysts Think Urogen Pharma (URGN) Could Surge 27.14%: Read This Before Placing a Bet
Are You Looking for a Top Momentum Pick? Why Urogen Pharma (URGN) is a Great Choice
Nvidia In Buy Zone, Leads 24 Newbies Onto Best Stock Lists
Urogen Pharma (URGN) Reports Q2 Loss, Tops Revenue Estimates
Insmed (INSM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
UroGen Pharma: Reimbursement Is Turning Zusduri Into A Workflow Moat (NASDAQ:URGN)